Aerial view of Suzhou Industrial Park in Suzhou, East China's Jiangsu Province, where biomedicine stands as one of the park's signature industries. Photo: VCG

The global pharmaceutical landscape is shifting, and China's innovative drug industry is expanding overseas at speed. A clear supply-demand shift began in 2023 and peaked in 2025, marking a period of value realization for the sector.

Many multinationals, hit by patent cliffs and insufficient internal pipelines, urgently need differentiated assets to fill the gap. China's pharmacy industry, driven by the 2015 regulatory reforms, policy support, a strong industrial chain, deep talent pools, and rising R&D spending, has steadily built global competitiveness. A growing number of proprietary global-first drug candidates are reaching international markets, and cross-border licensing deals are getting bigger and more strategic.

At the forefront stands InnoCare Pharma. In 2025, the company secured a global partnership with Zenas worth over $2 billion in its autoimmune disease pipeline. Its independently developed orelabrutinib, which was designated as a national "Major New Drug Development" project, is the world's only BTK inhibitor to demonstrate efficacy in a Phase II clinical trial for systemic lupus erythematosus.

The inclusion of innovative drugs among the "new new three" and their global success reflect China's innovation capabilities and R&D strength. After years of work, Chinese biopharma has made a remarkable leap. Looking ahead, we expect continued progress in overseas clinical development and commercialization to unlock even greater global value.


The author is co-founder, chairwoman & CEO of InnoCare Pharma. bizopinion@globaltimes.com.cn